Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema A Systematic Review

被引:89
|
作者
Yilmaz, Taygan [1 ]
Weaver, Christopher D. [1 ]
Gallagher, Micheal J. [2 ]
Cordero-Coma, Miguel [3 ]
Cervantes-Castaneda, Rene A. [4 ]
Klisovic, Dino [5 ]
Lavaque, Alejandro J. [6 ]
Larson, Robin J. [1 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03766 USA
[2] Hermitage Med Clin, Dublin, Ireland
[3] Hosp Leon, Dept Ophthalmol, Leon, Spain
[4] CODET Vis Inst, Tijuana, Mexico
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Oftalmol Cristo Alvarez, San Miguel De Tucuman, Argentina
关键词
RANDOMIZED CLINICAL-TRIAL; RETINOPATHY; PHOTOCOAGULATION;
D O I
10.1016/j.ophtha.2009.02.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). Clinical Relevance: Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. Methods and Literature Reviewed: The following databases were searched: Medline (1950-September Week 2 2008), The Cochrane Library (Issue 3, 2008), and the TRIP Database (up to September 1, 2008), using no language or other limits. Randomized controlled trials were included that consisted of patients with refractory DME, those comparing IVTA injection with no treatment or STTA injection, those reporting VA outcomes, and those having a minimum follow-up of 3 months. Results: In the 4 randomized clinical trials comparing IVTA injection with placebo or no treatment, IVTA injection demonstrated greater improvement in VA at 3 months, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. Intravitreal triamcinolone acetonide injection demonstrated no difference in IOP at 3 months or at 6 months. Conclusions: Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:902-913 (C) 2009 by the American Academy of Ophthalmology.
引用
收藏
页码:902 / 911
页数:10
相关论文
共 50 条
  • [31] Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema
    Ozdek, Sengul
    Bahceci, Umut Asli
    Gurelik, Gokhan
    Hasanreisoglu, Berati
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2006, 20 (04) : 246 - 251
  • [32] Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema
    Jonas, JB
    Degenring, RF
    Kamppeter, BA
    Kreissig, I
    Akkoyun, I
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 138 (01) : 158 - 160
  • [33] Intravitreal injection versus sub-tenon's infusion of triamcinolone acetonide for the management of refractory diabetic macular edema
    Jorge, R
    Bonini, MA
    Calucci, D
    Cardillo, JA
    Costa, RA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [34] Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema
    Jonas, JB
    Degenring, R
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2002, 219 (06) : 429 - 432
  • [35] A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
    Abdelshafy Tabl, Ahmed
    Tawfik Soliman, Tarek
    Anany Elsayed, Mohamed
    Abdelshafy Tabl, Marwa
    JOURNAL OF OPHTHALMOLOGY, 2022, 2022
  • [36] INTRAVITREAL INJECTION VERSUS SUBTENON INFUSION OF TRIAMCINOLONE ACETONIDE DURING CATARACT SURGERY IN PATIENTS WITH REFRACTORY DIABETIC MACULAR EDEMA
    Takata, Clecio
    Messias, Andre
    Folgosa, Marco S.
    Lucena, Levy R.
    Lucena, Daniel R.
    Scott, Ingrid U.
    Jorge, Rodrigo
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (04): : 562 - 569
  • [37] Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema
    Conway, MD
    Canakis, C
    Livir-Rallatos, C
    Peyman, GA
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2003, 29 (01): : 27 - 33
  • [38] Comparison of the Efficacy Between an Intravitreal and a Posterior Subtenon Injection of Triamcinolone Acetonide for the Treatment of Diffuse Diabetic Macular Edema
    Qamar, Rao Muhammad Rashad
    Saleem, Muhammad Imran
    Saleem, Muhammad Farhan
    EURASIAN JOURNAL OF MEDICINE, 2013, 45 (03): : 185 - 190
  • [39] Association between pre-treatment variables and response to intravitreal triamcinolone acetonide injection in diabetic macular edema
    Ahmad, S
    Stinnett, SS
    Jaffe, GJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [40] Intravitreal injection of triamcinolone for diffuse diabetic macular edema
    Wong, R
    Sherefat, H
    Bartholomew, D
    Horgan, SE
    ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (07) : 1082 - 1082